These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17043706)

  • 1. Management of overactive bladder with transdermal oxybutynin.
    Starkman JS; Dmochowski RR
    Rev Urol; 2006; 8(3):93-103. PubMed ID: 17043706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.
    Zobrist RH; Quan D; Thomas HM; Stanworth S; Sanders SW
    Pharm Res; 2003 Jan; 20(1):103-9. PubMed ID: 12608543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of oxybutynin chloride topical gel for overactive bladder.
    Lucente VR; Staskin DR; De E
    Open Access J Urol; 2011 Apr; 3():35-42. PubMed ID: 24198634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.
    Cohn JA; Brown ET; Reynolds WS; Kaufman MR; Milam DF; Dmochowski RR
    Ther Adv Urol; 2016 Apr; 8(2):83-90. PubMed ID: 27034721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
    Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW
    World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review.
    Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
    Res Rep Urol; 2020; 12():321-330. PubMed ID: 32884926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxybutynin topical gel in the treatment of overactive bladder.
    Davila GW
    Open Access J Urol; 2010 Jun; 2():91-8. PubMed ID: 24198618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal oxybutynin: for overactive bladder.
    Bang LM; Easthope SE; Perry CM
    Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
    Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
    Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.